sphingosine kinase-2 (SK2) inhibitor


Redhill Biopharma’s Opaganib Shows Promise Among 6 Hospitalized COVID-19 Patients in Israel via Compassionate Use Program

RedHill Biopharma Ltd (RDHL), a specialty biopharmaceutical company, reports that all six hospitalized patients with confirmed SARS-CoV-2 infection (the cause of COVID-19) that received their experimental drug opaganib (Yeliva®) demonstrated measurable clinical...

Pin It on Pinterest